

# REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form for  
File Information Unit  
Crystal Plaza Three, Room 1100  
2021 South Clark Place  
Arlington, VA  
Telephone: (703) 305-2738

**RECEIVED**

FEB 25 2004

File Information Unit

In re Application of

Reiter et al.

Application Number

09/636801

Filed

8-10-00

Paper No.

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. 2003/0165504, page, line

United States Patent Number, column, line, or

WIPO Pub. No., page, line

## Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:  
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

- the pending application as originally filed.

Signature

J. LUCUDINE

Typed or printed name

Registration Number, if applicable

703-413-0600

Telephone Number

Date

2-25-04

**RECEIVED**

Approved by

FEB 25 2004

File Information Unit

Best Available Copy



US 20030165504A1

(19) **United States**(12) **Patent Application Publication**  
**Retter et al.**(10) **Pub. No.: US 2003/0165504 A1**(43) **Pub. Date: Sep. 4, 2003**(54) **COMPOSITIONS AND METHODS FOR THE  
THERAPY AND DIAGNOSIS OF OVARIAN  
CANCER**(76) **Inventors: Marc W. Retter, Carnation, WA (US);  
Gary R. Fanger, Mill Creek, WA (US)****Correspondence Address:**  
**SEED INTELLECTUAL PROPERTY LAW**  
**GROUP PLLC**  
**701 FIFTH AVE**  
**SUITE 6300**  
**SEATTLE, WA 98104-7092 (US)**(21) **Appl. No.: 09/827,271**(22) **Filed: Apr. 4, 2001****Related U.S. Application Data**(63) **Continuation-in-part of application No. 09/667,857,  
filed on Sep. 29, 2000, which is a continuation-in-part  
of application No. 09/636,801, filed on Aug. 10, 2000,  
now abandoned, which is a continuation-in-part of  
application No. 09/617,747, filed on Jul. 17, 2000,  
now abandoned, which is a continuation-in-part of  
application No. 09/404,879, filed on Sep. 24, 1999,  
now Pat. No. 6,468,546, which is a continuation-in-****part of application No. 09/338,933, filed on Jun. 23,  
1999, now Pat. No. 6,488,931, which is a continua-  
tion-in-part of application No. 09/216,003, filed on  
Dec. 17, 1998, and which is a continuation-in-part of  
application No. 09/215,681, filed on Dec. 17, 1998,  
now Pat. No. 6,528,253.****Publication Classification**(51) **Int. Cl.<sup>7</sup> ..... A61K 39/395; C12N 9/00;  
C07K 16/40**(52) **U.S. Cl. .... 424/146.1; 435/183; 530/388.26**(57) **ABSTRACT**

Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.